Franceschi E.; Mura A.; Lamberti G.; De Biase D.; Tosoni A.; Di Battista M.; Argento C.; Visani M.; Paccapelo A.; Bartolini S.; Brandes A.A., Concordance between RTOG and EORTC prognostic criteria in low-grade gliomas, «FUTURE ONCOLOGY», 2019, 15, pp. 2595 - 2601 [articolo]
Lamberti, Giuseppe; Brighi, Nicole; Campana, Davide, Current Management and Predictive Factors of Lymph Node Metastasis of Appendix Neuroendocrine Tumors: A National Study From the French Group of Endocrine Tumors (GTE), «ANNALS OF SURGERY», 2019, 270, pp. 43 - 44 [replica/breve intervento]
Brighi N.; Lamberti G.; Campana D., Cutaneous Scapular Lesion in an Elderly Woman, «JAMA ONCOLOGY», 2019, 5, pp. 1355 - 1356 [articolo]
Lamberti G.; Andrini E.; Ricciuti B., Impact of performance status and age on osimertinib efficacy in patients with EGFR-mutant T790M-positive non-small-cell lung cancer, «JOURNAL OF THORACIC DISEASE», 2019, 11, pp. S1831 - S1834 [articolo]
Franceschi, Enrico; Tosoni, Alicia; De Biase, Dario; Lamberti, Giuseppe; Danieli, Daniela; Pizzolitto, Stefano; Zunarelli, Elena; Visani, Michela; Di Oto, Enrico; Mura, Antonella; Minichillo, Santino; Scafati, Chiara; Asioli, Sofia; Paccapelo, Alexandro; Bartolini, Stefania; Brandes, Alba A, Postsurgical Approaches in Low-Grade Oligodendroglioma: Is Chemotherapy Alone Still an Option?, «THE ONCOLOGIST», 2019, 24, pp. 664 - 670 [articolo]
Gelsomino, Francesco; Lamberti, Giuseppe; Parisi, Claudia; Casolari, Laura; Melotti, Barbara; Sperandi, Francesca; Ardizzoni, Andrea, The evolving landscape of immunotherapy in small-cell lung cancer: A focus on predictive biomarkers, «CANCER TREATMENT REVIEWS», 2019, 79, Article number: 101887, pp. 1 - 11 [articolo]
Brighi N.; Lamberti G.; Manuzzi L.; Maggio I.; Campana D., Therapeutic options in lung neuroendocrine tumors: between established concepts and new hopes, «ANTI-CANCER DRUGS», 2019, 30, pp. 649 - 654 [articolo]
Panzuto F.; Campana D.; Massironi S.; Faggiano A.; Rinzivillo M.; Lamberti G.; Sciola V.; Lahner E.; Manuzzi L.; Colao A.; Annibale B., Tumour type and size are prognostic factors in gastric neuroendocrine neoplasia: A multicentre retrospective study, «DIGESTIVE AND LIVER DISEASE», 2019, 51, pp. 1456 - 1460 [articolo]
Lamberti G.; Peterle C.; Gelsomino F., Darpp-32 and t-darpp isoform in non-small cell lung cancer (nsclc): Could they drive patients' clinical management and be a therapeutic target?, «TRANSLATIONAL LUNG CANCER RESEARCH», 2018, 7, pp. S326 - S328 [replica/breve intervento]
Marinelli A.; Lamberti G.; Cerbone L.; Cordua N.; Buonerba C.; Peluso G.; Di Lorenzo G.; De Placido S., High-dose fotemustine in temozolomide-pretreated glioblastoma multiforme patients, «MEDICINE», 2018, 97, Article number: e11254, pp. 1 - 5 [articolo]Open Access
Lamberti G.; Franceschi E.; Brandes A.A., The burden of oncology promises not kept in glioblastoma, «FUTURE NEUROLOGY», 2018, 13, pp. 1 - 4 [articolo]
Franceschi E, Mura A, De Biase D, Tallini G, Pession A, Foschini MP, Danieli D, Pizzolitto S, Zunarelli E, Lanza G, Bartolini D, Silini EM, Visani M, Di Oto E, Tosoni A, Minichillo S, Lamberti G, Lanese A, Paccapelo A, Bartolini S, Brandes AA, The role of clinical and molecular factors in low-grade gliomas: What is their impact on survival?, «FUTURE ONCOLOGY», 2018, 14, pp. 1559 - 1567 [articolo]
Lamberti, Giuseppe; Brighi, Nicole; Maggio, Ilaria; Manuzzi, Lisa; Peterle, Chiara; Ambrosini, Valentina; Ricci, Claudio; Casadei, Riccardo; Campana, Davide, The Role of mTOR in Neuroendocrine Tumors: Future Cornerstone of a Winning Strategy?, «INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES», 2018, 19, Article number: 747, pp. 1 - 17 [articolo]Open Access
Franceschi E.; Lamberti G.; Paccapelo A.; Di Battista M.; Genestreti G.; Minichillo S.; Mura A.; Bartolini S.; Agati R.; Brandes A.A., Third-line therapy in recurrent glioblastoma: is it another chance for bevacizumab?, «JOURNAL OF NEURO-ONCOLOGY», 2018, 139, pp. 383 - 388 [articolo]
Lamberti, G; Ceccarelli, C; Brighi, N; Maggio, I; Santini, D; Mosconi, C; Ricci, C; Biasco, G; Campana, D., Determination of Mammalian Target of Rapamycin Hyperactivation as Prognostic Factor in Well-Differentiated Neuroendocrine Tumors, «GASTROENTEROLOGY RESEARCH AND PRACTICE», 2017, 2017, pp. 1 - 9 [articolo]Open Access
